API | sitravatinib

sitravatinib Report issue

Small molecule Experimental

AACT MeSH PubChem

Active Ingredient History

NOW

Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases. ^Wikipedia

Chemistry

SMILES: COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)cc4F)c3s2)nc1.O=C(O)CC(O)C(=O)O
InChIKey: GDLGZWLGDROYHH-UHFFFAOYSA-N
Mol. Mass: 763.78
ALogP: 6.52 Partition coefficient
ChEMBL Molecule:
sitravatinib malate

More Chemistry

Pharmacology

Mechanisms of Action:
- Hepatocyte growth factor receptor (Homo sapiens) ^UniProt
- Tyrosine-protein kinase Mer (Homo sapiens) ^UniProt
- Mast/stem cell growth factor receptor Kit (Homo sapiens) ^UniProt
- Tyrosine-protein kinase receptor UFO (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

mgcd516 | sitravatinib | sitravatinib tislelizumab

Organizations (19)

Research & Development (19)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (28)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (28)

Biliary Tract Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Early Phase 1)

Carcinoma, Transitional Cell (Phase 2)

Drugs, Investigational (Phase 2)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 1/Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Healthy Volunteers (Phase 1)

Kidney Neoplasms (Phase 1/Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Liposarcoma (Phase 2)

Liver Diseases (Phase 1)

Lung Diseases (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 3)

Melanoma (Phase 2)

Mutation (Phase 2)

Nasopharyngeal Carcinoma (Phase 1)

Neoplasms (Phase 2/Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Stomach Neoplasms (Phase 1/Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 39
# of Trial Organizations: 19

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue